Aegerion Pharmaceuticals Appoints Mary Szela as Chief Executive Officer
07 janv. 2016 09h24 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
10 déc. 2015 08h30 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
JUXTAPID™ (lomitapide) Capsules Available on the Régie de l'Assurance Maladie du Québec (RAMQ) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
20 nov. 2015 08h30 HE
|
Aegerion Pharmaceuticals, Inc.
TORONTO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with...
Capsules de JUXTAPIDMC (lomitapide) disponibles sur la Liste des médicaments de la Régie de l'assurance maladie du Québec (RAMQ) pour le traitement de l’hypercholestérolémie familiale homozygote (HFHo)
20 nov. 2015 08h30 HE
|
Aegerion Pharmaceuticals, Inc.
TORONTO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc., société biopharmaceutique se consacrant à l’élaboration et à la commercialisation de thérapies innovantes pour des patients...
JUXTAPID™ (lomitapide) Capsules Available on the Régie de l'Assurance Maladie du Québec (RAMQ) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
20 nov. 2015 08h30 HE
|
Aegerion Pharmaceuticals, Inc.
TORONTO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for...
Aegerion Pharmaceuticals to Present at the Jefferies Autumn 2015 Global Healthcare Conference
13 nov. 2015 08h30 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Announces Results From First Year of LOWER Study at AHA Scientific Sessions 2015
10 nov. 2015 16h35 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals Announces Third Quarter 2015 Financial Results
09 nov. 2015 16h05 HE
|
Aegerion Pharmaceuticals, Inc.
- Company records $67.3 million in total net product sales - CAMBRIDGE, Mass., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company...
Aegerion Pharmaceuticals Announces Postponement of Third Quarter 2015 Financial Results Conference Call
05 nov. 2015 08h20 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
Aegerion Pharmaceuticals to Announce Third Quarter 2015 Financial Results on Thursday, November 5
29 oct. 2015 16h05 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...